Brainstorm Cell director granted 150,000 options

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

BRAINSTORM CELL THERAPEUTICS INC. director Stacy Lindborg received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. All 150,000 options were outstanding after the grant.

The options were granted under the company’s 2014 Stock Incentive Plan. According to the terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, provided she remains employed through each vesting date. The options expire on February 26, 2036, giving a long-dated incentive tied to the company’s future share performance.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider Lindborg Stacy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.70	$105K

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
2. F2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

Options granted: 150,000 options Exercise price: $0.70 per share Underlying shares: 150,000 shares +2 more

5 metrics

Options granted 150,000 options Stock Option (Right to Buy) grant to director

Exercise price $0.70 per share Conversion or exercise price for granted options

Underlying shares 150,000 shares Common Stock underlying the options

Shares after grant 150,000 derivative securities Stock options held following the transaction

Option expiration February 26, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), 2014 Stock Incentive Plan, vesting, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2014 Stock Incentive Plan financial

"granted under the Issuer's 2014 Stock Incentive Plan"

vesting financial

"The Stock Options shall vest as to (i) 50% of the award"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BCLI director Stacy Lindborg report in this Form 4?

Stacy Lindborg reported receiving stock options to buy 150,000 shares of Brainstorm Cell Therapeutics common stock. The award is compensation, not an open-market purchase, and was granted under the company’s 2014 Stock Incentive Plan with a fixed exercise price and vesting schedule.

How many BCLI stock options were granted to Stacy Lindborg?

She was granted options for 150,000 shares of Brainstorm Cell Therapeutics common stock. These options give her the right to buy that number of shares at a preset exercise price, subject to the vesting conditions and long-dated expiration disclosed in the filing.

What is the exercise price of Stacy Lindborg’s BCLI stock options?

The exercise price is $0.70 per share for the 150,000 stock options. This means she can later purchase Brainstorm Cell Therapeutics common shares at $0.70, if the options are vested and she chooses to exercise them before the stated expiration date.

When do Stacy Lindborg’s BCLI stock options vest?

Half of the options vest on the grant date and the remaining half vest six months after the grant date. Vesting is contingent on her remaining employed by Brainstorm Cell Therapeutics through each applicable vesting date, aligning ongoing service with the equity award.

When do Stacy Lindborg’s Brainstorm Cell Therapeutics options expire?

The options expire on February 26, 2036, according to the filing. After this expiration date, any unexercised options will lapse, so potential value from the grant depends on share performance and decisions made before that long-term deadline.

Is Stacy Lindborg’s BCLI Form 4 a market buy or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market buy. The transaction code “A” and description show it is a grant or award of stock options under the 2014 Stock Incentive Plan, providing future purchase rights instead of an immediate market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 06:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lindborg Stacy

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$0.7	02/26/2026		A		150,000		(2)	02/26/2036	Common Stock	150,000	$0.7(1)	150,000	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Stacy Lindborg	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)